FAIL molecules and uses thereof

Details FAIL molecules and uses thereof FAIL molecules and uses thereof

2006-09-19

2006-09-19

Turner, Sharon (Department: 1649)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C435S069100, C435S320100, C435S252300, C435S254200

Reexamination Certificate

active

07109319

ABSTRACT:
The invention provides isolated nucleic acid molecules, designated FAIL, which encode polypeptide molecules containing Ig and Ig-like domains and which are homologous to FcγRI. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

REFERENCES:
patent: 5198342 (1993-03-01), Maliszewski
patent: 5328987 (1994-07-01), Maliszewski
patent: 5506126 (1996-04-01), Seed et al.
patent: 5985599 (1999-11-01), McKenzie et al.
patent: 6287820 (2001-09-01), Umansky et al.
patent: 2004/0034192 (2004-02-01), Kato et al.
patent: WO 99/40117 (1999-08-01), None
patent: WO 99/46281 (1999-09-01), None
patent: WO 00/28032 (2000-05-01), None
patent: WO 00/28032 (2000-05-01), None
patent: WO 00/32767 (2000-06-01), None
patent: WO 01/49728 (2001-07-01), None
patent: WO 01/49728 (2001-07-01), None
Skolnick and Fetrow (2000) From Genes to Protein Structure and Function: Novel Applications of Compuational Approaches the Genomic Era. Trends in Biotech 18(1); 34-39.
Wells, J.A. Additivity of Mutational Effects of Proteins (1990) Biochemistry 29(37): 8509-8517.
Davis et al. (2002) Identification of a family of Fc Receptor homologs with referential B cell expression. PNAS 98(17): 9772-9777.
Bork (2000) Powers and Pitfalls in Sequence Analysis: The 70% Hurdle. Genome Research 10: 398-400.
Doerks (1998) Protein Annotation: detective work for function prediction. TIG 14(6): 248-250.
Smith and Zhang (1997) The Challenges of genome sequence annotation or “The Devil is in the details”. Nature Biotechnology 15: 1222-1223.
Brenner (1999) Erros in genome annotation TIG 15(4): 132-133.
Bork and Bairoch (1996) Go Hunting in sequence databases but watch out for the traps. TIG 12(10): 425-427.
Bendayan (1995) Possibilities of False Immunocytochemical Results Generated by the Use of Monoclonal Antibodies: The Example of the Anti-proinsulin Antibody. The Journal of Histochemistry and Cytochemistry 43(9): 881-886.
Seaman et al. (1991) Molecular Cloning of gp42, A cell-sruface molecule that is selectively induced on rat natural kill cell by interluekin 2: Glycolipid membrane anchoring and capacity for transmembrane signaling. J. Exp. Med. 251-260.
Mechetina et al. (Jan. 2002) “FCRL, a novel member of the leukocyte Fc receptor family possesses unique structural features.” European Journal of Immunology 32(1): 87-96.
Neto et al. (Mar. 28, 2000) “Shotgun sequencing of the human transcriptome with ORF expressed sequence tags.” PNAS 97(7): 3491-3496.
Ngo et al. (Mar. 2, 1995) “The Protein Folding Problem and Tertiary Structure Prediction, Chapter 14: Computational Complexity Protein Structure Prediction, and the Levinthal Paradox” pp. 492-495.
Bieber et al. (Oct. 1996) “New insights in the structure and biology of the high affinity receptor for lgE (FceRl) on human epidermal Langerhans cells.” J Dermatol Sci. 13(1): 71-75.
Capel et al. (Feb. 1994) “Heterogeneity of human lgG Fc Receptors.” Immunomethods 4(1): 25-34.
“Nucleic Acid Hybridization- General Aspects” pp. 33-37 Roche website retrieved on May 12, 2004.
NIH Division of Intramural Research “Nucleic Acid Hybridization” retrieved from NIH website on May 12,2004.
Marshall “Gene Therapy's Growing Pains”. Science, vol. 269 (1995), pp. 1050-1055.
Verma I.M. et al. 1997. Nature 389:239-242.
Orkin S.H. et al. 1995. “Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy”.
Hopp et al., Proc Natl Acad Sci USA 78:3824-2828.
Stratagene Catalog, 1991, p. 66.
Wiesmann 2000. J. Mol. Med 78:247-260.
Van de Winkel, J.F.J. et al. “lgG Fc receptor 1” Apr. 27, 1993 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on Apr. 9, 2001]. GenBank Accession No. AAA35678.
“FC gamma Rlla [Homo sapiens]” Jul. 21, 1994 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on Apr. 9, 2001]. GenBank Accession No. CAA01563.
Kochan, J., et al. “High Affinity Immunoglobulin Epsilon Receptor Alpha-Subunit Precursor (FCERI) (IGE FC Receptor, Alpha-Subunit) (FC-Epsilon Rl-Alpha)” Oct. 1, 2000 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on Apr. 9, 2001]. GenBank Accession No. P12319.
Ng, S. et al. “Low Affinity Immunoglobulin Gamma FC Region Receptor II-B Precursor (FC-Gamma RII-B) (FCRII-B) (IGG FC receptor II-B) (FC Gamma-RIIB) (CD32) (CDW32)”. May 30, 2000 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on Apr. 9, 2001]. GenBenk Accession No. P31994.
Stuart S.G., et al. “Low Affinity Immunoglobulin Gamma FC Region Receptor II-C Precursor (FC-Gamma RII-C) (FCRII-C) (IGG FC Receptor II-C) (FC-GAMMARIIC) (CD32) (CDW32)”. Oct. 1, 2000 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on Apr. 9, 2001]. GenBank Accession No. P31995.
Ravetch, J.V. and Perussia, B. “Low Affinity Immunoglobulin Gamma FC Region Receptor III-A Precursor (IGG FC Receptor III-2—(FC-Gamma RIII-Alpha) (FC-Gamma RIIIA) (FCRIIIA) (FC-GAMMA RIII) (FCRIII) (CD16-A) (FCR-10)” May 30, 2000 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on Apr. 9, 2001]. GenBank Accession No. P08637.
Allen, J.M. and Seed, B. “Human mRNA for High Affinity Fc Receptor (FcRI) ‘b form’” Sep. 12, 1993 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on Apr. 9, 2001]. GenBank Accession No. X14355.
Bateman, A. et al. “Immunoglobulin Domain” (database result) Pfam [online] St. Louis, MO, USA, Washington University School of Medicine [retrieved Apr. 9, 2001]. Accession No. PF00047.
Altschul, Stephen F. et al., “Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs”Nucleic Acids Researchvol. 25, No. 17 (Sep. 1, 1997), pp. 3389-3402.
Atschul, Stephen F. et al., “Basic Local Alignment Search Tool”Journal of Molecular Biologyvol. 215 (Oct. 5, 1990), pp. 403-410.
Barnes, Peter J. “Therapeutic Strategies for Allergic Diseases”Naturevol. 402 (supp) (Nov. 25, 1999) pp. B31-B38.
Buck, Clayton A., “Immunoglobulin Superfamily: Structure, Function and Relationship to other Receptor Molecules”Seminars in Cell Biologyvol. 3 (Jun. 1992) pp. 179-188.
Corry, David B. and Kheradmand, F. “Induction and Regulation of the IgE Response”Naturevol. 402 (supp) (Nov. 25, 1999) pp. B18-B23.
Daëron, Marc, “Fc Receptor Biology”Annual Review Immunologyvol. 15 (1997) pp. 203-234.
Emara, Mohamed and Sanfilippo, F. “The Inhibition of T Cell Proliferative Responses by Crosslinking CD7 and IgM-Fc Receptors”Cellular Immunologyvol. 144 (Oct. 1, 1992) pp. 143-154.
Emara, Mohamed and Carroll, R.G., “Signal Transduction Through Crosslinking CD7 and IgM-Fc Receptors that Inhibits T-Cell Proliferation”Human Immunologyvol. 34 (Jul. 1992) pp. 181-195.
Heyman, Birgitta, “Regulation of Antibody Responses Via Antibodies, complement, and Fc Receptors”Annual Review Immunologyvol. 18 (2000) pp. 709-737.
Holgate, Stephen T. “The Epidemic of Allergy and Asthma”Naturevol. 402 (supp) ( Nov. 25, 1999) pp. B2-B4.
Karlin, Samuel and Altschul, S.F., “Applications and Statistics for Mul

Affiliated with

Also associated with

Rating

FAIL molecules and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with FAIL molecules and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and FAIL molecules and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3603704